FDA
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
-
-
-
-
-
-
-
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
-
-
-
-
-
-
-
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
-
-
-
-
-
-
-
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
-
-
-
-
-
-
-
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

